Data / Drug companies / Macleods Pharmaceuticals Limited
Macleods Pharmaceuticals Limited: 390 products in the FDA NDC directory, labeler code 33342
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Macleods Pharmaceuticals Limited (labeler code 33342) lists 390 products in the FDA National Drug Code Directory, covering 130 finished drugs by generic name. By type: 374 prescription drugs, 16 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 15, 2026.
The request: Watch Macleods Pharmaceuticals Limited (FDA labeler code 33342): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 33342
- Products in commercial distribution
- 390
- Packages
- 1,082
- Finished drugs by generic name
- 130
- Prescription products
- 374
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 6, Schedule V 12
- Flagged as original packager
- 345 of 345 products that carry the flag
- Started marketing in the last 12 months
- 31
- Products with a marketing end date set
- 1
- Earliest marketing start
- January 13, 2012
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 374 | 95.9% |
| Bulk ingredients | 16 | 4.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 374 | 95.9% |
| Bulk ingredients | 16 | 4.1% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 121 | 31% |
| Tablet | 114 | 29.2% |
| Capsule | 36 | 9.2% |
| Tablet, extended release | 26 | 6.7% |
| Powder | 16 | 4.1% |
| Capsule, extended release | 16 | 4.1% |
| Capsule, delayed release | 11 | 2.8% |
| Ointment | 9 | 2.3% |
| Tablet, orally disintegrating | 8 | 2.1% |
| Solution | 7 | 1.8% |
| Cream | 5 | 1.3% |
| Tablet, film coated, extended release | 5 | 1.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Milnacipran Hydrochloride | 33342-372 | Tablet | Generic drugs (ANDA) | September 15, 2026 |
| Milnacipran Hydrochloride | 33342-371 | Tablet | Generic drugs (ANDA) | September 15, 2026 |
| Milnacipran Hydrochloride | 33342-370 | Tablet | Generic drugs (ANDA) | September 15, 2026 |
| Milnacipran Hydrochloride | 33342-369 | Tablet | Generic drugs (ANDA) | September 15, 2026 |
| Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate oral | 33342-546 | Solution | Generic drugs (ANDA) | August 31, 2026 |
| Nintedanib esylate | 33342-551 | Capsule | Generic drugs (ANDA) | August 3, 2026 |
| Nintedanib esylate | 33342-550 | Capsule | Generic drugs (ANDA) | August 3, 2026 |
| Dapsone | 33342-535 | Tablet | Generic drugs (ANDA) | July 8, 2026 |
| Dapsone | 33342-534 | Tablet | Generic drugs (ANDA) | July 8, 2026 |
| Chlorthalidone | 33342-426 | Tablet | Generic drugs (ANDA) | July 1, 2026 |
| Chlorthalidone | 33342-425 | Tablet | Generic drugs (ANDA) | July 1, 2026 |
| Rifapentine | 33342-599 | Tablet, film coated | Generic drugs (ANDA) | June 23, 2026 |
| Bupropion Hydrochloride (SR) | 33342-528 | Tablet, extended release | Generic drugs (ANDA) | June 23, 2026 |
| Bupropion Hydrochloride (SR) | 33342-527 | Tablet, extended release | Generic drugs (ANDA) | June 23, 2026 |
| Bupropion Hydrochloride (SR) | 33342-526 | Tablet, extended release | Generic drugs (ANDA) | June 23, 2026 |
| Tofacitinib | 33342-542 | Tablet, film coated | Generic drugs (ANDA) | June 3, 2026 |
| Tofacitinib | 33342-541 | Tablet, film coated | Generic drugs (ANDA) | June 3, 2026 |
| Dapagliflozin | 33342-586 | Tablet | Generic drugs (ANDA) | April 6, 2026 |
| Dapagliflozin | 33342-585 | Tablet | Generic drugs (ANDA) | April 6, 2026 |
| Dapagliflozin and Metformin Hydrochloride | 33342-409 | Tablet, extended release | Generic drugs (ANDA) | April 6, 2026 |
| Dapagliflozin and Metformin Hydrochloride | 33342-408 | Tablet, extended release | Generic drugs (ANDA) | April 6, 2026 |
| Dapagliflozin and Metformin Hydrochloride | 33342-407 | Tablet, extended release | Generic drugs (ANDA) | April 6, 2026 |
| Dapagliflozin and Metformin Hydrochloride | 33342-406 | Tablet, extended release | Generic drugs (ANDA) | April 6, 2026 |
| Mexiletine Hydrochloride | 33342-557 | Capsule | Generic drugs (ANDA) | March 23, 2026 |
| Mexiletine Hydrochloride | 33342-556 | Capsule | Generic drugs (ANDA) | March 23, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.